Jardiance has been approved for HFpEF on the strength of the EMPEROR-Preserved trial, which showed the drug reduced the risk of cardiovascular death or hospitalisation for heart failure in adults ...
The study showed that treatment with ... rival SGLT2 inhibitor Jardiance (empagliflozin) in the EMPEROR-Preserved in July 2021 in heart failure preserved ejection fraction (HFpEF).
Summary of key findings: The DELTA-HF feasibility study is continuing to enroll patients in Europe. A randomized controlled trial will begin in the United States, Canada and Europe later this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback